Corcept resubmits NDA for relacorilant to FDA for Cushing's syndrome; six-month review expected

CORCEPT THERAPEUTICS INC

• Resubmission based on pivotal GRACE trial and Phase III GRADIENT trial data.
• Includes additional analyses requested by FDA; expects six-month review cycle.
• Relacorilant shows durable symptom improvement without serious adverse events like hypokalemia or pregnancy termination.
• CEO states company looks forward to working with FDA toward approval.